Agenus (AGEN) Q3 2024 earnings summary

Executive summary

• Botensilimab and balstilimab (BOT/BAL) are demonstrating unprecedented efficacy in MSS colorectal cancer and other hard-to-treat tumors, with promising results presented at ESMO GI 2024 and further data expected in 2025.

• Patient access initiatives, including Compassionate Use and Named Patient Programs, are expanding global access to BOT/BAL outside clinical trials.

• Strategic focus includes operational cost reductions, asset monetization, and advanced discussions on transformative transactions to secure long-term growth.

• The company has prioritized its lead program, accelerating development and commercialization while reducing workforce and postponing other programs.

• Collaborations with major pharma partners provide milestone and royalty opportunities.

Financial highlights

• Ended Q3 2024 with $44.8 million in cash, down from $76.1 million at year-end 2023; subsequently raised $7.1 million through stock sales.

• Q3 2024 revenue was $25.1 million, with nine-month revenue at $76.6 million, both up year-over-year.

• Net loss for Q3 2024 was $67.2 million and $185.5 million for the nine months, including significant non-cash expenses.

• Cash used in operations for the first nine months of 2024 was $129.7 million, a reduction from $183.8 million in the same period of 2023.

• Research and development expenses decreased 27% year-over-year to $121.8 million; general and administrative expenses decreased 11% to $50.9 million.

Outlook and guidance

• Anticipates early 2025 data readouts from two European neoadjuvant studies in colorectal and other solid tumors, as well as maturing Phase 2 data in refractory colorectal cancer.

• Additional BOT/BAL trial results in MSS CRC and other cancers expected at major oncology conferences in early 2025.

• Phase 3 trial design for BOT/BAL has received FDA and EMA feedback; initiation contingent on securing strategic partnerships or financing.

• Management is actively pursuing funding through partnerships, asset sales, royalty monetization, and equity offerings.

• Substantial doubt exists about the company’s ability to continue as a going concern for one year after the report date.